pf-06412562

Small moleculeexperimental

Clinical trial activity

11 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
11
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Aug 1, 2013 (NCT01914796)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • pf-06412562

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04457310Phase 1/Phase 2 (Phase 2)Nov 30, 2020Cerevel Therapeutics, LLC, Columbia University, Stony Brook University, University of Pennsylvania, Yale University
NCT03665454Phase 1Sep 24, 2018Pennsylvania State University, Pfizer
NCT03686501Early Phase 1 (Phase 1)Jul 6, 2018Invicro
NCT03181841Phase 1May 8, 2017Pfizer, University of Zurich
NCT02418819Phase 1Apr 1, 2015Pfizer
NCT02306876Phase 1Jan 1, 2015Pfizer
NCT02201511Phase 1Sep 1, 2014Pfizer
NCT02124213Phase 1Sep 1, 2014Pfizer
NCT02006290Phase 1Mar 1, 2014Pfizer
NCT01959594Phase 1Nov 1, 2013Pfizer
NCT01914796Phase 1Aug 1, 2013Pfizer
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PfizerFor profit9712013
Cerevel Therapeutics, LLCFor profit1012020
Columbia UniversityAcademic/Hospital1012020
InvicroFor profit1112018
Pennsylvania State UniversityAcademic/Hospital1112018
Stony Brook UniversityAcademic/Hospital1012020
University of PennsylvaniaAcademic/Hospital1012020
University of ZurichAcademic/Hospital1112017
Yale UniversityAcademic/Hospital1112020
9 organizations
Page 1 / 1